Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23521538 | 0.78 | TSHR (0.30) | — | |
| SCHEMBL680882 | 0.78 | ALDH1A1 (0.40) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL23518445 | 0.78 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL20220965 | 0.77 | — | — | |
| SCHEMBL13386672 | 0.76 | — | — | |
| SCHEMBL2757994 | 0.76 | TDP1 (0.40) | — | |
| SCHEMBL5174067 | 0.76 | ALDH1A1 (0.39) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL14727208 | 0.76 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1515322 | 0.76 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12083942 | 0.76 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11826432-B2 | Linkers, conjugates and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220395581-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-12-15 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-20220143194-A1 | SELENIUM ANTIBODY CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8557765-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2013-10-15 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2009-12-17 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7553842-B2 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | HMGCR 2178/4885CHRM1 106/4885TBXA2R 179/4885 |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | HMGCR 2218/4885CHRM1 3521/4885TBXA2R 3907/4885 |
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MLNR, GIPR, GRPR | HMGCR 4756/4885CHRM1 2979/4885TBXA2R 547/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HMGCR 1907/4885CHRM1 4731/4885TBXA2R 1420/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HMGCR 1907/4885CHRM1 4731/4885TBXA2R 1420/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | HMGCR 978/4885CHRM1 1642/4885TBXA2R 165/4885 |
| US-11826432-B2 | Linkers, conjugates and applications thereof | CD44, EPCAM, MSN | HMGCR 2201/4885CHRM1 2645/4885TBXA2R 2515/4885 |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CD44, EPCAM, MSN | HMGCR 2201/4885CHRM1 2645/4885TBXA2R 2515/4885 |
| US-20220143194-A1 | SELENIUM ANTIBODY CONJUGATES | SCLY, SELENOI, GPX1 | HMGCR 1556/4885CHRM1 4399/4885TBXA2R 4697/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | HMGCR 2106/4885CHRM1 249/4885TBXA2R 246/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | HMGCR 2106/4885CHRM1 249/4885TBXA2R 246/4885 |
| US-20220395581-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CD44, EPCAM, MSN | HMGCR 2201/4885CHRM1 2645/4885TBXA2R 2515/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | HMGCR 3765/4885CHRM1 39/4885TBXA2R 3578/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | HMGCR 2325/4885CHRM1 427/4885TBXA2R 248/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HMGCR 1907/4885CHRM1 4731/4885TBXA2R 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.